PROVERA (medroxyprogesterone acetate) by Pfizer is (mpa) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. First approved in 1959.
Drug data last refreshed 8h ago · AI intelligence enriched 4d ago
PROVERA (medroxyprogesterone acetate) is an oral progestin tablet approved in 1959 that works by inhibiting gonadotropin secretion to prevent ovulation and thicken cervical mucus. It is indicated for contraception and other gynecological conditions requiring progesterone therapy. The drug represents a foundational hormonal contraceptive with decades of clinical use.
Product approaching loss of exclusivity with modest Part D volume signals defensive positioning and potential team consolidation.
(MPA) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
Worked on PROVERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PROVERA offers deep experience in lifecycle management, defensive strategy, and generic transition—critical skills for mature brand stewardship at large pharma. However, the product's LOE trajectory and minimal linked job openings signal limited near-term growth opportunities and potential team restructuring.